AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36934740 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2·4 mg once weekly
Number of subjects: 71
Study 36934740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 36934894 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided SBRT to the prostate bed (30-34 Gy in five fractions)
Number of subjects: 31
Study 36934894 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive planning following initial treatment plans
Number of subjects: 31
Study 36934978 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy
Number of subjects: 387
Study 36934980 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized mean arterial pressure (MAP) management
Number of subjects: 1100
Study 36934980 — intervention group
Group type: COMPARATOR
Intervention: MAP of 65 mm Hg or more (Control)
Number of subjects: 1100
Study 36934980 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized MAP management
Number of subjects: 1100
Study 36934987 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic regulation therapy (ART) utilizing cervical vagus nerve stimulation (VNS)
Number of subjects: 52
Study 36935024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose whole brain radiation therapy (LD-WBRT) at 2 Gy × 5 over 1 week
Number of subjects: 5
Study 36935089 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted computerized antimicrobial stewardship intervention
Number of subjects: 2470
Study 36935089 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2470
Study 36935199 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) with connective tissue graft (CTG)
Number of subjects: 28
Study 36935199 — intervention group
Group type: COMPARATOR
Intervention: Tunnel technique (TUN) with connective tissue graft (CTG)
Number of subjects: 28
Study 36935288 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA plasmid encoding HIV-1 subtype B nef/tat/vif and env (n=11)
Number of subjects: 14
Study 36935288 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=3)
Number of subjects: 14
Study 36935691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' education on delirium control
Number of subjects: 371
Study 36935691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' assessment practices
Number of subjects: 371
Study 36935691 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with nurses' knowledge
Number of subjects: 371
Study 36935691 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to effective delirium control
Number of subjects: 371
Study 36936230 — intervention group
Group type: EXPERIMENTAL
Intervention: Radspherin® administered intraperitoneally 2 days after CRS-HIPEC; dose escalation at 1-2-4-7 MBq; evaluated for safety and tolerability.
Number of subjects: 23
Study 36936230 — intervention group
Group type: EXPERIMENTAL
Intervention: Radspherin®
Number of subjects: 23
Study 36936243 — intervention group
Group type: EXPERIMENTAL
Intervention: RTA test
Number of subjects: 150
Study 36936402 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g C19-IG20%
Number of subjects: 461
Study 36936402 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g C19-IG20%
Number of subjects: 461
Study 36936402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 461
Study 36936523 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed home therapy adherence combined with TheraBracelet (subsensory random-frequency vibratory stimulation)
Number of subjects: 12
Study 36936523 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 12
Study 36936551 — intervention group
Group type: EXPERIMENTAL
Intervention: JET + PCB
Number of subjects: 40
Study 36936551 — intervention group
Group type: COMPARATOR
Intervention: PTA + PCB
Number of subjects: 40
Study 36936553 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital supplemental oxygen
Number of subjects: 2187
Study 36936553 — intervention group
Group type: EXPERIMENTAL
Intervention: No intensive care unit admission
Number of subjects: 2187
Study 36936553 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 2187
Study 36936553 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal haemorrhage
Number of subjects: 2187
Study 36936553 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboembolic event
Number of subjects: 2187
Study 36936553 — intervention group
Group type: EXPERIMENTAL
Intervention: Congestive heart failure
Number of subjects: 2187
Study 36936553 — intervention group
Group type: EXPERIMENTAL
Intervention: Subphenotype with most severe hospital course
Number of subjects: 2187
Study 36936553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate severity subphenotype with more comorbidities
Number of subjects: 2187
Study 36936553 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall persistent symptoms
Number of subjects: 2187
Study 36936553 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional status
Number of subjects: 2187
Study 36936918 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific antiviral immunity transfer from HCT donors (vaccinated or with a history of COVID-19)
Number of subjects: 0
Study 36936925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ig fractions from patients with AIS during COVID-19
Number of subjects: 70
Study 36936925 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyclonal anti-β2-GPI IgG
Number of subjects: 70
Study 36936952 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month interval between second and third doses of COVID-19 vaccine
Number of subjects: 171
Study 36936952 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-month interval between second and third doses of COVID-19 vaccine
Number of subjects: 171
Study 36936952 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 171
Study 36936952 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts (3-month and 5-month intervals)
Number of subjects: 171
Study 36936952 — intervention group
Group type: EXPERIMENTAL
Intervention: NAb seroconversion
Number of subjects: 171
Study 36937103 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency rTMS
Number of subjects: 0
Study 36937103 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 0
Study 36937520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 12
Study 36937520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 36937712 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+CBT4CBT
Number of subjects: 0
Study 36937712 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 0
Study 36937864 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36937912 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative psychological intervention (EXPECT), adapted to be brief for integration into routine care.
Number of subjects: 0
Study 36937912 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study 36937990 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE + CRT (arm B)
Number of subjects: 120
Study 36937990 — intervention group
Group type: COMPARATOR
Intervention: TACE (arm A)
Number of subjects: 120
Study 36938082 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic handgrip exercise program (group A)
Number of subjects: 119
Study 36938082 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced handgrip exercise program (group B)
Number of subjects: 119
Study 36938082 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced-plus upper arm banding program (group C)
Number of subjects: 119
Study 36938380 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0
Study 36938380 — intervention group
Group type: COMPARATOR
Intervention: Present-centered group therapy (PCGT)
Number of subjects: 0
Study 36938380 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based practices
Number of subjects: 0
Study 36938582 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 420
Study 36938582 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 420
Study 36938582 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour glucose
Number of subjects: 420
Study 36938582 — intervention group
Group type: EXPERIMENTAL
Intervention: OGTT or HbA1c
Number of subjects: 420
Study 36938582 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose and HbA1c
Number of subjects: 420
Study 36938587 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and continuous glucose monitoring (CGM)
Number of subjects: 91
Study 36938587 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 91
Study 36938587 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pancreas size and shape analysis
Number of subjects: 91
Study 36938627 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel sleep-wake classifier
Number of subjects: 31
Study 36938756 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical screening intervention for DCM risk management
Number of subjects: 1241
Study 36938756 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 1241
Study 36938985 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot caudal anaesthesia with 0.8 ml kg -1 of 2 mg kg -1 bupivacaine solution (group L, n = 29)
Number of subjects: 58
Study 36938985 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot caudal anaesthesia with 1.25 ml kg -1 of 2 mg kg -1 bupivacaine solution (group H, n = 29)
Number of subjects: 58
Study 36939067 — intervention group
Group type: EXPERIMENTAL
Intervention: V114 (15-valent pneumococcal conjugate vaccine)
Number of subjects: 407
Study 36939067 — intervention group
Group type: COMPARATOR
Intervention: PCV13 (13-valent pneumococcal conjugate vaccine)
Number of subjects: 407
Study 36939067 — intervention group
Group type: EXPERIMENTAL
Intervention: V114 followed by PPSV23
Number of subjects: 407
Study 36939067 — intervention group
Group type: COMPARATOR
Intervention: PCV13 followed by PPSV23
Number of subjects: 407
Study 36939067 — intervention group
Group type: EXPERIMENTAL
Intervention: V114
Number of subjects: 407
Study 36939067 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSV23 after V114
Number of subjects: 407
Study 36939180 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of shoulder dislocations
Number of subjects: 892
Study 36939180 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age, male sex, non-White race
Number of subjects: 892
Study 36939180 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact sport participation
Number of subjects: 892
Study 36939180 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder Activity Scale
Number of subjects: 892
Study 36939180 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive apprehension test
Number of subjects: 892
Study 36939180 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lesions
Number of subjects: 892
Study 36939601 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic memory and management aid (EMMA) tablet application
Number of subjects: 32
Study 36939601 — intervention group
Group type: EXPERIMENTAL
Intervention: Training usage of EMMA
Number of subjects: 32
Study 36939601 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching the aid to individuals with average-level language abilities
Number of subjects: 32
Study 36939601 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouraging early and frequent use of the aid during training
Number of subjects: 32
Study 36939629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesnatilimab 400 mg SC
Number of subjects: 388
Study 36939629 — intervention group
Group type: COMPARATOR
Intervention: Placebo SC
Number of subjects: 388
Study 36939629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesnatilimab 50 mg, 150 mg, 400 mg SC
Number of subjects: 388
Study 36939629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 36939629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab ~6 mg/kg IV at Week 0 and 90 mg SC at Weeks 8 and 16
Number of subjects: 388
Study 36939629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesnatilimab
Number of subjects: 388
Study 36939679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural-based intervention combined with mindfulness, psychoeducation, and relaxation techniques
Number of subjects: 0
Study 36939679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural-based intervention
Number of subjects: 0
Study 36939679 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 0
Study 36939728 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Care for Kids Ontario (CCKO) program
Number of subjects: 144
Study 36939728 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waitlist group)
Number of subjects: 144
Study 36939774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment
Number of subjects: 185
Study 36939801 — intervention group
Group type: EXPERIMENTAL
Intervention: sEH inhibitors
Number of subjects: 500
Study 36939801 — intervention group
Group type: COMPARATOR
Intervention: sEH activity
Number of subjects: 500
Study 36939815 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) combined with standard-of-care rehabilitation for 8 weeks
Number of subjects: 34
Study 36939815 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care rehabilitation for 8 weeks
Number of subjects: 34
Study 36939815 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT using the POWERbreathe K5 IMT device
Number of subjects: 34
Study 36939815 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of dyspnea using Medical Research Council Scale and 18-point qualitative dyspnea descriptors
Number of subjects: 34
Study 36939815 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic thickening fraction using ultrasound
Number of subjects: 34
Study 36939815 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle endurance
Number of subjects: 34
Study 36939815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function
Number of subjects: 34
Study 36939815 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefrontal cortical activity using functional near-infrared spectroscopy
Number of subjects: 34
Study 36939815 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic capacity during cardiopulmonary exercise testing
Number of subjects: 34
Study 36939815 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life using Short Form-36
Number of subjects: 34
Study 36939815 — intervention group
Group type: EXPERIMENTAL
Intervention: Scores from the Depression, Anxiety, and Stress scale-21
Number of subjects: 34
Study 36939818 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation program
Number of subjects: 44
Study 36939818 — intervention group
Group type: COMPARATOR
Intervention: Education and unstructured physical activity
Number of subjects: 44
Study 36939832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin MDA at 300 μg/kg for 3 consecutive days, provided under supervision to all eligible village inhabitants, over 2 successive rainy seasons.
Number of subjects: 14
Study 36939832 — intervention group
Group type: COMPARATOR
Intervention: Standard measures (seasonal malaria chemoprevention [SMC] and bed net use for children aged 3 to 59 months) and placebo.
Number of subjects: 14
Study 36939832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin MDA
Number of subjects: 14
Study 36939832 — intervention group
Group type: COMPARATOR
Intervention: Standard measures and placebo
Number of subjects: 14
Study 36939876 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-stage breast cancer patients
Number of subjects: 30
Study 36939879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of diaphragmatic thickness (Tdi) at inspiration
Number of subjects: 137
Study 36939879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of diaphragmatic thickness (Tdi) at expiration
Number of subjects: 137
Study 36939879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of diaphragm thickening fraction (dTF)
Number of subjects: 137
Study 36939879 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater reliability of ultrasound measurements
Number of subjects: 137
Study 36939932 — intervention group
Group type: COMPARATOR
Intervention: Severe-critical group
Number of subjects: 428
Study 36939932 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic/Pain/Dermatologic component
Number of subjects: 428
Study 36939932 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory/Fever/Fatigue/Psychiatric component
Number of subjects: 428
Study 36939932 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic/Pain/Dermatologic and Respiratory/Fever/Fatigue/Psychiatric components
Number of subjects: 428
Study 36939932 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial symptoms
Number of subjects: 428
Study 36939933 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 3285
Study 36940069 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once daily or 15 mg if creatinine clearance was between 30 and 49 mL/min)
Number of subjects: 64
Study 36940137 — intervention group
Group type: EXPERIMENTAL
Intervention: Grayson technique
Number of subjects: 30
Study 36940137 — intervention group
Group type: COMPARATOR
Intervention: Figueroa technique
Number of subjects: 30
Study 36940214 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical-Psychological Integrative (PPI) intervention group
Number of subjects: 72
Study 36940214 — intervention group
Group type: COMPARATOR
Intervention: Control group (didactic education program)
Number of subjects: 72
Study 36940261 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus PEGPH20 (n = 66)
Number of subjects: 79
Study 36940261 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (mFOLFOX6 or gemcitabine plus nab-paclitaxel) (n = 42)
Number of subjects: 79
Study 36940261 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus PEGPH20 (n = 13)
Number of subjects: 79
Study 36940261 — intervention group
Group type: COMPARATOR
Intervention: Control (ramucirumab plus paclitaxel) (n = 12)
Number of subjects: 79
Study 36940407 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated hepatic perfusion (IHP) with melphalan
Number of subjects: 93
Study 36940407 — intervention group
Group type: COMPARATOR
Intervention: Best alternative care (Control)
Number of subjects: 93
Study 36940437 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day hybrid therapy
Number of subjects: 918
Study 36940437 — intervention group
Group type: COMPARATOR
Intervention: 14-day high-dose dual therapy
Number of subjects: 918
Study 36940437 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day bismuth quadruple therapy
Number of subjects: 918
Study 36940444 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of apixaban twice daily for 30 days
Number of subjects: 1217
Study 36940444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1217
Study 36940444 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of apixaban
Number of subjects: 1217
Study 36940739 — intervention group
Group type: EXPERIMENTAL
Intervention: BAP-EB attachment rate in women aged ≥35 years having a live birth
Number of subjects: 240
Study 36940739 — intervention group
Group type: EXPERIMENTAL
Intervention: BAP-EB attachment rate
Number of subjects: 240
Study 36940771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum video education
Number of subjects: 161
Study 36940771 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (bedside coaching)
Number of subjects: 161
Study 36940793 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced hybrid closed-loop (AHCL) system (Minimed 780G®)
Number of subjects: 46
Study 36940793 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCL system (Minimed 780G®)
Number of subjects: 46
Study 36940951 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 0
Study 36940951 — intervention group
Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 0
Study 36941030 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow (HF) oxygen therapy at flow rates of 2 L/kg for the first 10 kg, plus 0.5 L/kg for every kg >10 kg
Number of subjects: 107
Study 36941030 — intervention group
Group type: COMPARATOR
Intervention: Low-flow (LF) oxygen therapy with a maximum flow rate of 3 L/min
Number of subjects: 107
Study 36941030 — intervention group
Group type: COMPARATOR
Intervention: Low-flow (LF) oxygen therapy
Number of subjects: 107
Study 36941030 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow (HF) oxygen therapy
Number of subjects: 107
Study 36941099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord length: 2 cm
Number of subjects: 99
Study 36941099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord length: 3 cm
Number of subjects: 99
Study 36941099 — intervention group
Group type: COMPARATOR
Intervention: Control group (not measured)
Number of subjects: 99
Study 36941099 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 99
Study 36941133 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,3-Beta-D-Glucan (BDG) concentration in peritoneal fluid
Number of subjects: 113
Study 36941133 — intervention group
Group type: EXPERIMENTAL
Intervention: BDG threshold of 125 pg/mL
Number of subjects: 113
Study 36941133 — intervention group
Group type: EXPERIMENTAL
Intervention: BDG concentrations in peritoneal fluid
Number of subjects: 113
Study 36941155 — intervention group
Group type: EXPERIMENTAL
Intervention: M-001 (1.0-mg)
Number of subjects: 120
Study 36941155 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 120
Study 36941402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment
Number of subjects: 0
Study 36941575 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA-guided chemotherapy
Number of subjects: 1621
Study 36941575 — intervention group
Group type: COMPARATOR
Intervention: Standard of care chemotherapy
Number of subjects: 1621